Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Oncology

• Publication date

  2003-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2003.04.042PMID 14551301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recognition Through an IL-12-Dependent Mechanism 1

  2003cited by this paper
• Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

  2003cited by this paper
• Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells

  2001cited by this paper
• Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

  2001cited by this paper
• A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection

  2001cited by this paper
• Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development.

  2001cited by this paper
• Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity.

  2001cited by this paper
• Phase I Trial Of Intravenous Peptide-Pulsed Dendritic Cells in Patients With Metastatic Melanoma

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment.

  2000cited by this paper
• Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways.

  1999cited by this paper
• A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

  1999cited by this paper
• Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

  1999cited by this paper
• Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone‐refractory metastatic disease

  1999cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• High-level IL-12 production by human dendritic cells requires two signals.

  1998cited by this paper
• Dendritic cells as the terminal stage of monocyte differentiation.

  1998cited by this paper
• Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype.

  1997cited by this paper
• A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells.

  1997cited by this paper
• Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells.

  1997cited by this paper
• CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

  1996cited by this paper
• Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

  1995cited by this paper
• Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

  1994cited by this paper
• Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes

  1991cited by this paper

• Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges

  2026cites this paper
• Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions

  2025cites this paper
• Advances in dendritic cell-based therapeutic tumor vaccines.

  2025cites this paper
• Tumor-draining lymph nodes - friend or foe during immune checkpoint therapy?

  2025cites this paper
• Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on Anti-Tumor Efficacy

  2025cites this paper
• Vaccine approaches to treat urothelial cancer

  2024cites this paper
• Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases

  2024cites this paper
• COMPARITIVE STUDY OF DENDRITIC CELL VACCINE PREPARATION WITH PRESENCE AND ABSENCE OF MALPIGHIA EMARGINATA FRUIT EXTRACT USING TUMOR RNA TRANSFECTION METHOD: A PROMISING APPROACH FOR PROSTATE CANCER

  2023cites this paper
• Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia

  2023cites this paper
• Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development.

  2023cites this paper
• Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251

  2023cites this paper
• Research progress on dendritic cell vaccines in cancer immunotherapy

  2022cites this paper
• Lymph Nodes as Anti-Tumor Immunotherapeutic Tools: Intranodal-Tumor-Specific Antigen-Pulsed Dendritic Cell Vaccine Immunotherapy

  2022cites this paper
• Capture and reagent exchange (CARE) wells for cell isolation, labeling, and characterization

  2022cites this paper
• Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial

  2021cites this paper
• Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis

  2021cites this paper
• Recent Advances in Cell‐Mediated Drug Delivery Systems for Nanomedicine and Imaging

  2021cites this paper
• Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting

  2020cites this paper
• Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy

  2020cites this paper
• Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites

  2020cites this paper
• Immune Cell Vaccine for Cancer

  2019cites this paper
• Improved dendritic cell therapy for cancer by enhancing in vivo lymph node migration using a novel chemokine-based sorting method

  2019cites this paper
• New Strategies to Improve Therapeutic Vaccines

  2018cites this paper
• Immunological Cellular Therapies and Gene Therapies

  2018cites this paper
• Dendritic Cells: The Tools for Cancer Treatment

  2018cites this paper
• Advances in immunotherapeutic research for glioma therapy

  2018cites this paper
• Immunotherapy for Brain Tumors

  2018cites this paper
• 19F-MRI to Monitor Therapeutic Cell Migration and Distribution

  2018cites this paper
• Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents

  2018cites this paper
• Efficacy and safety analysis on dendritic cell-based vaccine-treated high-grade glioma patients: a systematic review and meta-analysis

  2018cites this paper
• Cellular immunotherapy of cancer: an overview and future directions.

  2017cites this paper
• Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses.

  2017cites this paper
• EXOSOME MEDIATED INNATE AND ADAPTIVE IMMUNE STIMULATION FOR TREATMENT OF CANCER

  2017cites this paper
• Dendritic Cells as Targets of Vaccines and Adjuvants

  2017cites this paper
• Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

  2017cites this paper
• Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer

  2017cites this paper
• [Dendritic cell-based therapeutic cancer vaccines].

  2016cites this paper
• Expression of cancer testis antigens in patients with Hodgkin's lymphoma and their clinical correlation

  2016cites this paper
• Developing immunotherapeutic strategies to target brain tumors

  2016cites this paper
• Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression

  2016cites this paper
• Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses.

  2016cites this paper
• a 2 ) United States Patent

  2016cites this paper
• Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells

  2016cites this paper
• Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.

  2015cites this paper
• Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy

  2015cites this paper
• Parenteral Vaccine Administration: Tried and True

  2015cites this paper
• Visualization of fluid drainage pathways in lymphatic vessels and lymph nodes using a mouse model to test a lymphatic drug delivery system.

  2015cites this paper
• Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy

  2015cites this paper
• Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

  2015cites this paper
• Dendritic cell vaccine against leukemia: advances and perspectives.

  2014cites this paper
• RNAVaccines in Cancer Treatment

  2014cites this paper
• Cancer Vaccines

  2014cites this paper
• Dendritic Cell Vaccination

  2014cites this paper
• Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?

  2014cites this paper
• Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?

  2014cites this paper
• Optimizing Dendritic Cell-Based Approaches for Cancer Immunotherapy

  2014cites this paper
• Various ways to improve whole cancer cell vaccines

  2014cites this paper
• The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.

  2014cites this paper
• Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle

  2014cites this paper
• Intralymphatic immunotherapy and vaccination in mice.

  2014cites this paper
• Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts

  2013cites this paper
• A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

  2013cites this paper
• Immunodiagnostics and immune surveillance in an era of evolving immunotherapeutic strategies in AML

  2013cites this paper
• Monitoring immune responses in dendritic cell based vaccination with a focus on in vivo imaging

  2013cites this paper
• Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.

  2013cites this paper
• Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS

  2013cites this paper
• IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.

  2013cites this paper
• Therapeutic dendritic cell-based cancer vaccines: the state of the art.

  2013cites this paper
• Vaccines against advanced melanoma.

  2013cites this paper
• RNA pulsed dendritic cells: an approach for cancer immunotherapy.

  2013cites this paper
• A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer

  2013cites this paper
• HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ

  2012cites this paper
• Immunotherapy for melanoma

  2012cites this paper
• New routes for allergen immunotherapy

  2012cites this paper
• A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

  2012cites this paper
• Advances in immunotherapy using dendritic cells

  2012cites this paper
• Immunotherapy for the Treatment of Glioblastoma

  2012cites this paper
• Trial watch

  2012cites this paper
• A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer

  2012cites this paper
• Improving Outcomes in Advanced Malignant Melanoma

  2012cites this paper
• Dendritic Cell-Based Cancer Vaccines: Practical Considerations

  2011cites this paper
• Caractérisation de DKK1 comme antigène tumoral et manipulation des lymphocytes T CD8 : utilisation de la voie de Wnt en immunothérapie du cancer

  2011cites this paper
• Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy

  2011cites this paper
• Assessment of TWIST1 as an immunotherapeutic target of cancer

  2011cites this paper
• Dendritic cell-tumor cell fusion vaccines.

  2011cites this paper
• Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

  2011cites this paper
• Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

  2011cites this paper
• Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

  2011cites this paper
• mRNA-Lipoplex loaded microbubble contrast agents for ultrasound-assisted transfection of dendritic cells.

  2011cites this paper
• Therapeutic vaccines in renal cell carcinoma.

  2011cites this paper
• Cell fusion in health and disease

  2011cites this paper
• Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.

  2010cites this paper
• Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075

  2010cites this paper
• Biology of Human Cutaneous Melanoma

  2010cites this paper
• Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma.

  2010cites this paper
• Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis

  2010cites this paper
• Clinical Cancer esearch cer Therapy : Clinical andomized Trial of Ex vivo CD 40 L Activation of a Dendritic l Vaccine in Colorectal Cancer Patients : Tumor-Specific R une Responses Are Associated with Improved Survival

  2010cites this paper
• Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters

  2010influential citation
• A Randomized Trial of Ex vivo CD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival

  2010cites this paper
• Using the TLR7/8 Agonist CL075 Generation of Th1-Polarizing Dendritic Cells

  2010cites this paper